期刊文献+

调经促孕丸联合氯米芬治疗肥胖型多囊卵巢综合征不孕的疗效观察 被引量:17

Clinical observation of Tiaojing Cuyun Pills combined with clomifene in treatment of obesity polycystic ovarian syndrome infertility
原文传递
导出
摘要 目的探究调经促孕丸联合枸橼酸氯米芬胶囊治疗肥胖型多囊卵巢综合征不孕的临床疗效。方法选取2014年6月—2017年3月到商南县中医医院接受治疗的肥胖型多囊卵巢综合症患者102例为研究对象,按随机数表法分为对照组和治疗组,每组各51例。对照组从月经周期第5天开始口服枸橼酸氯米芬胶囊,50 mg/次,1次/d。治疗组在对照组的基础上从月经周期第5天开始口服调经促孕丸,5 g/次,2次/d。1个月为1个疗程,两组患者均连续治疗3个疗程。观察和比较两组的排卵率、妊娠率、妊娠早期流产率、激素水平和子宫内膜厚度。结果治疗后,对照组和治疗组排卵率分别为71%、92%,妊娠率分别为69%、91%,妊娠早期流产率分别为10%、2%,两组排卵率、妊娠率、妊娠早期流产率比较差异具有统计学意义(P<0.05)。治疗后,两组卵泡刺激素(FSH)、黄体生成激素(LH)、LH/FSH水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组这些激素水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组子宫内膜厚度均显著减少,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组子宫内膜厚度明显小于对照组,两组比较差异具有统计学意义(P<0.05)。结论调经促孕丸联合枸橼酸氯米芬胶囊治疗肥胖型多囊卵巢综合征不孕具有较好的临床疗效,能降低FSH、LH水平,改善子宫内膜厚度,提高排卵率和妊娠率,降低妊娠早期流产率,具有一定的临床推广应用价值。 Objective To investigate the clinical effect of Tiaojing Cuyun Pills combined with Clomifene Citrate Capsules in treatment of obesity polycystic ovarian syndrome infertility. Methods Patients(102 cases) with obesity polycystic ovarian syndrome infertility in Shangnan County Chinese Medicine Hospital from June 2014 to March 2017 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Clomifene Citrate Capsules from the fifth day of menstrual cycle, 50 mg/time, once daily. Patients in the treatment group were po administered with Tiaojing Cuyun Pills on the basis of the control group, 5 g/time, twice daily. One month was 1 course, and patients in two groups were treated for 3 courses. After treatment, the ovulation rate, pregnancy rate, early pregnancy abortion rate, hormone level, and endometrial thickness in two groups were compared. Results After treatment, the ovulation rate in the control and treatment groups were 71% and 92%, respectively; the oviposit rates in the control and treatment groups were 69% and 91%, respectively, and the early pregnancy abortion rates in the control and treatment groups were 10% and 2%, respectively, and there was difference between two groups(P<0.05). After treatment, the levels of FSH, LH, and LH/FSH in two groups were significantly decreased, and the difference was statistically significant in the same group(P<0.05). And the hormone levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P<0.05). After treatment, the endometrial thicknesses in two groups were significantly decreased, and the difference was statistically significant in the same group(P<0.05). And the endometrial thickness in the treatment group was significantly thicker than that in the control group, with significant difference between two groups(P<0.05). Conclusion Tiaojing Cuyun Pills combined with Clomifene Citrate Capsules has clinical curative effect in treatment of obesity polycystic ovarian syndrome infertility, can decrease the levels of FSH and LH, improve the endometrial thickness, increase the ovulation rate and pregnancy rate, reduce the early pregnancy abortion rate, which has a certain clinical application value.
作者 周文勤 方典洲 ZHOU Wen-qin;FANG Dian-zhou(Department of Obstetrics and Gynecology, Shangnan County Chinese Medicine Hospital, Shangluo 726300, Chin)
出处 《现代药物与临床》 CAS 2018年第4期926-929,共4页 Drugs & Clinic
关键词 调经促孕丸 枸橼酸氯米芬胶囊 肥胖型多囊卵巢综合征不孕 排卵率 妊娠率 妊娠早期流产率 激素水平 子宫内膜厚度 Tiaojing Cuyun Pills Clomifene Citrate Capsules obesity polycystic ovarian syndrome infertility ovulation rate pregnancyrate early pregnancy abortion rate hormone level endometrial thickness
作者简介 周文勤(1972-),女,本科,副主任医师,研究方向为妇科肿瘤、内分泌和中西医结合治疗不孕症。Tel:13991442385E-mail:zhuzz116561@163.com
  • 相关文献

参考文献10

二级参考文献186

  • 1王必勤,林敏.清胃健脾法治疗肥胖型多囊卵巢综合征48例[J].山东中医药大学学报,2009,33(1):41-42. 被引量:8
  • 2施茵,虞莉青.多囊卵巢综合征与肥胖的关系及其中医治疗[J].针灸临床杂志,2010,26(2):61-65. 被引量:10
  • 3Shaveta M Malik,Michael L Traub.Defining the role of bariatric surgery in polycystic ovarian syndrome patients[J].World Journal of Diabetes,2012,3(4):71-79. 被引量:12
  • 4魏美荣,肖瑞丽.中西医结合治疗排卵障碍性不孕症278例效果分析[J].社区医学杂志,2006,4(06S):28-29. 被引量:2
  • 5欧阳惠卿.中医妇科学[M].北京:人民卫生出版社,2006:140-142.
  • 6Zawadzki JK,Dunaif A. Diagnostic criteria for polycystic ovary syndrome:towards a rational approach [M]//Dunaif A, Givens J, Haseltine F,et al. Polycystic ovary syndrome. Boston:Blackwell Scientific, 1992: 377.
  • 7Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome (PCOS)[J]. Hum Reprod, 2004,19( 1 ) :41-47.
  • 8Ning N, Balen A, Brezina PR, et al. How to recognize PCOS : results of a web-based survey at IVF-worldwide. corn [J]. Reprod Biomed Online, 2013,26(5 ) : 500-505.
  • 9Azziz R,Carmina E,Dewailly D,et al. Androgen Excess Society. Positions statement:criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline [J]. J Clin Endocrinol Metab,2006,91 ( 11 ) :4237-4245.
  • 10Japanese Society of Obstetrics and Gynecology (JSOG). Constitute of Reproductive endocrinology. Reports of a new diagnostic criteria of PCOS in Japan [J]. Acta Obstet Gynecol Jpn,2007,59:868- 886.

共引文献192

同被引文献196

引证文献17

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部